Skip to main content
. 2023 Sep 18;23:873. doi: 10.1186/s12885-023-11389-x

Table 4.

Multivariate analysis of prognostic factors for progression-free survival

Variables HR (95% CI) P value
Hepatitis
 Hepatitis B 1
 Other 0.769 (0.499, 1.186) 0.235
PLR 1.003 (1.000, 1.006) 0.031
Ascites
 Present 1
 Absent 0.645 (0.434, 0.959) 0.030
Treatment method
 Atez/Bev 1
 TACE-Atez/Bev 0.461 (0.311, 0.684) < 0.001

HR Hazard ratio, CI Confidence interval, PLR Platelet-to-lymphocyte ratio, Atez/Bev Atezolizumab/bevacizumab, TACE Transarterial chemoembolization